Finance entity
Across an 85-day span, the pace is roughly 0.4 stories per week. The busiest single day carried 2. Coverage clusters in markets, which accounts for 3 of those 5, with the remainder spread across 1 other category. Source depth averages 3.6 original sources per story, versus 2.6 across the same-window beat baseline.
Last mentioned: Mar 21, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Across an 85-day span, the pace is roughly 0.4 stories per week. The busiest single day carried 2. Coverage clusters in markets, which accounts for 3 of those 5, with the remainder spread across 1 other category. Source depth averages 3.6 original sources per story, versus 2.6 across the same-window beat baseline. Their average consequence score of 5.2 runs below the beat's 6.3 for that window. Pomerantz Law Firm is most often covered alongside Navan, Inc., which appears in 2 of these 5 stories. Against the same-window beat baseline of 28% negative, this entity's 20% share is less negative. This profile follows 5 Finance stories mentioning Pomerantz Law Firm across the period from February 20, 2026 to May 15, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 2870 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pomerantz Law Firm. Shared-story counts are live from our verified record — not editorial picks.
Discovery Phase Begins
Courts likely to rule on motions to dismiss, leading to the exchange of internal corporate documents.
Announcement of Lawsuits
Pomerantz Law Firm releases press statements reminding investors of class action lawsuits and upcoming deadlines for Medpace Holdings, Inc. and zSpace, Inc.
Lead Plaintiff Deadline (Estimated)
Expected window for investors to file motions to lead the class actions against RARE, MREO, and NAVAN.
Coordinated Legal Alerts
Pomerantz Law Firm issues a series of reminders for class action deadlines across four major firms.
Investors in Medpace Holdings and zSpace face urgent deadlines for class action lawsuits, potentially leading to significant financial recoveries amid market volatility. This development underscores the risks in healthcare and tech stocks, with implications for portfolio diversification and regulatory compliance in finance.
Source: prnewswire.com · prnewswire.com
Pomerantz Law Firm has initiated dual investigations into Encompass Health Corporation and Victoria's Secret & Co. regarding potential securities fraud and unlawful business practices. These probes signal rising litigation risk for the healthcare and retail sectors as investors scrutinize corporate disclosures and guidance accuracy.
Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Trip.com Group, Aquestive Therapeutics, and Driven Brands Holdings. These legal actions focus on alleged securities violations and material misrepresentations that resulted in significant shareholder losses.
Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications.
Pomerantz Law Firm has initiated a series of investigations into seven companies, including Snowflake and Navan, regarding potential securities fraud and unlawful business practices. These probes target firms across the technology, finance, and healthcare sectors, signaling a heightened period of legal scrutiny for public entities.
Source: prnewswire.com · prnewswire.com
Pomerantz Law Firm is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
